Folate Functionalized PLGA Nanoparticles Loaded with Plasmid pVAX1-NH36: Mathematical Analysis of Release
Source abstract
Abstract
Plasmid DNA (pVAX1-NH36) was encapsulated in nanoparticles of poly-dl-lactic-co-glycolic (PLGA) functionalized with polyethylene glycol (PEG) and folic acid (PLGA-PEG-FA) without losing integrity. PLGA-PEG-FA nanoparticles loaded with pVAX1-NH36 (pDNA-NPs) were prepared by using a double emulsification-solvent evaporation technique. PLGA-PEG-FA synthesis was verified by FT-IR and spectrophotometry methods. pVAX1-NH36 was replicated in Escherichia coli (E. coli) cell cultures. Atomic force microscopy (AFM) analysis confirmed pDNA-NPs size with an average diameter of 177–229 nm, depending on pVAX1-NH36 loading and zeta potentials were below −24 mV for all preparations. In vitro release studies confirmed a multiphase release profile for the duration of more than 30-days. Plasmid release kinetics were analyzed with a release model that considered simultaneous contributions of initial burst and degradation-relaxation of nanoparticles. Fitting of release model against experimental data presented excellent correlation. This mathematical analysis presents a novel approach to describe and predict the release of plasmid DNA from biodegradable nanoparticles.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanotechnology Graduate Program, Department of Physics, University of Sonora, Hermosillo 83000, Mexico
Department of Chemical and Metallurgical Engineering, University of Sonora, Hermosillo 83000, Mexico
Department of Scientific and Technological Research, University of Sonora, Hermosillo 83000, Mexico
Department of Chemical and Environmental Engineering, University of Arizona, Tucson, AZ 85721, USA
Funding
Consejo Nacional de Ciencia y Tecnología
References (62)
Show source-provided references
1. Introduction to drug delivery technology
2. Nanotechnology in drug delivery and tissue engineering: From discovery to applications10.1021/nl102184c ↗
3. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
4. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
5. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier10.3390/polym3031377 ↗
6. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices10.1016/S0142-9612(00)00115-0 ↗
7. Biodegradable polymeric nanoparticles based drug delivery systems10.1016/j.colsurfb.2009.09.001 ↗
8. PEG-coated nanospheres from amphiphilic diblock and multiblock copolymers: Investigation of their drug encapsulation and release characteristics10.1016/S0168-3659(96)01597-0 ↗
9. MAPLE deposition of PLGA:PEG films for controlled drug delivery: Influence of PEG molecular weight10.1016/j.apsusc.2011.10.044 ↗
10. Polymeric nanoparticles for cancer therapy10.1080/10611860701794353 ↗
11. Folic acid-decorated nanocomposites prepared by a simple solvent displacement method10.1002/mabi.201100344 ↗
12. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate10.1080/10611860802088630 ↗
13. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma10.1016/j.bmc.2011.05.016 ↗
14. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer10.1039/b702538f ↗
15. Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles10.1023/A:1013674200141 ↗
16. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles10.1016/S0032-5910(99)00182-5 ↗
17. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug10.1002/jps.21158 ↗
18. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles10.1073/pnas.0809154105 ↗
19. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: Effect of formulation variables on size, drug recovery and release kinetics10.1016/S0168-3659(02)00211-0 ↗
20. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis10.1016/j.vaccine.2004.04.015 ↗
21. Vaccines for visceral leishmaniasis: A review10.1016/j.jim.2015.03.017 ↗
22. A combination DNA vaccine encoding nucleoside hydrolase 36 and glycoproteine 63 protects female but not male hamsters against Leishmania mexicana10.1051/parasite/2009163227 ↗
23. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani10.1016/j.vaccine.2006.03.005 ↗
24. DNA vaccines induce partial protection against Leishmania mexicana10.1016/S0264-410X(02)00769-7 ↗
25. Scaling-up recombinant plasmid DNA for clinical trial: Current concern, solution and status10.1016/j.vaccine.2012.02.061 ↗
26. Vaccine candidates for leishmaniasis: A review10.1016/j.intimp.2011.05.008 ↗
27. Vaccines for leishmaniasis in the fore coming 25 years10.1016/j.vaccine.2008.01.023 ↗
28. Encapsulation of plasmid DNA in biodegradable poly(d,l-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery10.1016/S0168-3659(98)00099-6 ↗
29. Basto, P.A. (2013). Development of Polymeric Nanoparticle Vaccines for Immunostimulation. [Ph.D. Thesis, Massachusetts Institute of Technology].
30. Kunugi, S., and Yamaoka, T. (2012). Polymers in Nanomedicine, Springer. Advances in Polymer Science.10.1007/978-3-642-27856-3 ↗
31. Gene therapy progress and prospects: Synthetic polymer-based systems10.1038/gt.2008.105 ↗
32. Chitosan conjugated DNA nanoparticles in gene therapy10.1016/j.carbpol.2009.08.026 ↗
33. Nanoparticle mediated delivery of pure P53 supercoiled plasmid DNA for gene therapy10.1016/j.jconrel.2011.08.007 ↗
34. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice10.1111/pim.12042 ↗
35. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA10.1016/S0168-3659(01)00397-2 ↗
36. Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine10.2147/IJN.S70633 ↗
37. Controlled Release of Plasmid DNA from a Genetically Engineered Silk-Elastinlike Hydrogel10.1023/A:1016406120288 ↗
38. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review10.1016/j.ijpharm.2011.05.049 ↗
39. Modeling of drug release from bulk-degrading polymers10.1016/j.ijpharm.2010.12.020 ↗
40. Quantifying drug release from PLGA nanoparticulates10.1016/j.ejps.2009.04.004 ↗
41. Fitzgerald, J.F., and Corrigan, O.I. (1993). Polymeric Delivery Systems, American Chemical Society.
42. The thermal decomposition of potassium permanganate10.1039/tf9444000488 ↗
43. Synthesis, characterization and transfection of a novel folate-targeted multipolymeric nanoparticles for gene delivery10.1007/s10856-009-3750-0 ↗
44. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate10.1016/j.jconrel.2004.08.017 ↗
45. Preparation and Characterization of Folate Conjugated Nanoparticles of Doxorubicin using PLGA-PEG-FOL Polymer10.4172/2161-0444.1000117 ↗
46. Biodegradable nanoparticles for drug delivery and targeting10.1016/S1359-0286(02)00117-1 ↗
47. Lucero-Acuna, J.A. (2013). Synthesis and Characterization of Polymeric Nanoparticle Structures for Control Drug Delivery in cancer Therapies and Temperature Effects on Drug Release. [Ph.D. Thesis, The University of Arizona].
48. WSXM: A software for scanning probe microscopy and a tool for nanotechnology10.1063/1.2432410 ↗
49. Polymeric nanoparticles for pulmonary protein and DNA delivery10.1016/j.actbio.2014.01.033 ↗
50. Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery10.1016/j.biomaterials.2009.09.024 ↗
51. Assessment of purity and quantification of plasmid DNA in process solutions using high-performance hydrophobic interaction chromatography10.1016/S0021-9673(03)00618-6 ↗
52. Biodegradable polymeric nanoparticles as drug delivery devices10.1016/S0168-3659(00)00339-4 ↗
53. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres10.1021/js9604117 ↗
54. Nanoparticle encapsulation and controlled release of a hydrophobic kinase inhibitor: Three stage mathematical modeling and parametric analysis10.1016/j.ijpharm.2015.07.049 ↗
55. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles10.1016/S0142-9612(00)00040-5 ↗
56. A novel model and experimental analysis of hydrophilic and hydrophobic agent release from biodegradable polymers10.1002/jbm.a.32171 ↗
57. Layered double hydroxide as an efficient drug reservoir for folate derivatives10.1016/j.biomaterials.2003.09.083 ↗
58. Folic acid-conjugated chitosan nanoparticles enhanced protoporphyrin IX accumulation in colorectal cancer cells10.1021/bc9004798 ↗
59. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel10.1016/j.biomaterials.2009.09.036 ↗
60. Folate receptor targeted biodegradable polymeric doxorubicin micelles10.1016/j.jconrel.2004.02.003 ↗
61. Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles10.1016/j.colsurfb.2014.07.020 ↗
62. A biodegradable low molecular weight polyethylenimine derivative as low toxicity and efficient gene vector10.1021/bc800428y ↗